Abstract: Mucoepidermoid carcinoma (MEC) is a malignant epithelial neoplasm composed of varying proportions of mucous, epidermoid, intermediate, columnar, and clear cells and often demonstrates prominent cystic growth. MEC is usually subclassified as low, intermediate, or high grade on the basis of its histologic features, including the presence of cystic spaces, cellular differentiation, proportion of mucous cells, growth pattern, type of invasion, and cytologic atypia. Because even low-grade neoplasms may metastasize, the term mucoepidermoid tumor is inappropriate. The 3-level grading approach to tumor classification has found general acceptance among pathologists; differences in biologic behavior can be demonstrated even though clinical stage has become a better prognosticator. However, in the case of MEC, no universal agreement exists regarding which histologic grading criteria are most the useful, and grading has varied. These issues have led to the investigation of more subjective systems. We describe these new schemes, the histologic variants of MEC, and the ancillary methods that allow for further stratification of patients with MEC, especially for patients with grade 2 tumors, which have a variable and unpredictable clinical course.
T he recognition and definition of mucoepidermoid tumor as a distinct salivary gland neoplasm is largely a result of a study by Stewart et al, 1 who coined the term mucoepidermoid tumor in 1945. Since then, this neoplasm has become the subject of protracted controversies regarding the possible existence of a benign form, which histologic features are the most prognostically useful to formulate grades, and the optimal number of histologic grades. All salivary MECs have malignant potential; thus, the previously used noncommittal term ''mucoepidermoid tumor'' is no longer considered appropriate. Even lowgrade neoplasms can recur or metastasize to regional lymph nodes.
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EPIDEMIOLOGY
Although constituting less than 15% of all salivary gland tumors, MECs account for approximately 30% of all malignant salivary gland neoplasms that originate in both the major and minor glands and 22% and 41% of malignant tumors in the major and minor glands, respectively. 2, 3, [11] [12] [13] [14] [15] MEC is the most common primary malignant tumor in both adults and children; in children, most are low-grade neoplasms. 16 In adults, MECs are most common in the third to fifth decades of life (mean age 45 y). There is a 3:2 male:female predilection, except for tongue, retromolar, and intraosseous lesions, which are more common in women. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Rarely, MEC is associated with benign salivary gland tumors such as pleomorphic adenoma, Warthin tumor, and oncocytoma. Other combinations of unilateral synchronous and metachronous occurrences have been reported. 17 
ETIOLOGY
No chemical carcinogens or oncogenic viruses are associated with MEC, but prior exposure to ionizing radiation is clearly a contributing factor. Among survivors of the Hiroshima and Nagasaki atomic bomb explosions in 1945, the incidence of MEC is 44%, making it the most common salivary gland neoplasm. 18 Similarly, MEC has been reported after radiation therapy for thyroid carcinoma or leukemia. 19 The translocation of gene material, t(11;19) (q21;p13.1), has been identified as a solitary abnormality in some cases of MEC and may be an early event in pathogenesis. 20 Cloning of this translocation led to the identification of a fusion transcript of exon 1 of a novel gene termed MECT1. 21, 22 MECT1 is a gene of unknown function on 10p12-13, with exons 2% to 5% of the mastermindlike gene family (MAML2) at 11q21. The transcript is a notch gene coactivator and a newly discovered mechanism of MEC tumorigenesis. By reverse transcription-polymerase chain reaction, the transcript was identified in 2 of 4 MEC tissues and was undetectable in normal tissues, indicating an association between this transcript and MEC.
LOCALIZATION
Approximately 60% of MECs occur in the major salivary glands and 35% in the minor glands. 2, 3, 6 The parotid glands are the predominant site, representing 48% of cases, with 11% in the submandibular glands, and 1% in the sublingual glands. The palate and buccal mucosa are the most frequent sites in the minor salivary glands, followed by the antrum, tongue, gingiva, floor of the mouth, and nasal cavity. 3, 6 An ectopic salivary gland origin in the periparotid lymph nodes has also been reported. 23 Perhaps the most unusual location that has been reported is the mandible and maxilla. 24 
CLINICAL FINDINGS
The clinical presentation of MEC may vary according to the histologic grade. Low-grade and intermediate-grade MECs may present as slow-growing masses; high-grade MEC generally presents as a rapidly enlarging mass. [2] [3] [4] [5] [6] [7] [8] [9] [10] Regardless of the location, an asymptomatic swelling is the presenting symptom in 75% of cases; only 13% of patients experience associated pain. Parotid and submandibular tumors usually present as solitary painless masses confined to the preauricular or submandibular regions. Skin or deeper tissue fixation, partial or complete facial nerve paralysis, and tumor ulceration are rarely observed and are signs of high-grade lesions. The mean duration of MEC of the major salivary glands is 1.5 years.
Patients with MEC of the minor salivary glands have diverse clinical presentations. The tumors often masquerade as benign neoplastic and inflammatory conditions. Many lesions, especially in the palate, are fluctuant, bluish, smooth-surfaced swellings that resemble mucoceles. Depending on the location of the neoplasm, symptoms include dysphagia, dysphonia, pain, paresthesia, ulceration, or hemorrhage. 3, 6 In a study by Spiro et al, 6 enlarged cervical nodes, related to metastasis occurred in approximately 29% of patients. Nodal involvement was more common in patients with submandibular gland tumors and recurrent high-grade parotid lesions. Nodal enlargement was seldom found in patients with minor salivary gland neoplasms at presentation; the incidence of enlargement, recorded during the course of the disease, was similar to that observed in patients with parotid tumors. 6 
PATHOLOGY
Gross Findings
MEC tumors are firm, smooth, often cystic, tan, white, or pink, with well-defined or infiltrative borders. Low-grade tumors closely resemble benign cystic tumors (Fig. 1) . Intermediate-grade and high-grade MECs are usually infiltrative growths, and cystic formations are less pronounced than are those in low-grade tumors (Fig. 2) . In Armed Forces Institute of Pathology (AFIP) cases, the tumor size varied from less than 1 cm to more than 12 cm in the major salivary glands and as large as 5 cm in the minor glands.
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Histopathology
Cellular Components
The term MEC gives no indication that these tumors contain several types of cells; the term may be a contraction of the original designation, ''mixed epidermoid and mucous-secreting carcinoma.'' 2, 3, 6 Both terms emphasize mucous and epidermoid cells, but several other cell types are also found in MEC (Fig. 3 ). [1] [2] [3] [4] [5] [6] (1) ''Maternal'' Cells These cells are approximately the size of a lymphocyte and round or oval in shape and have small, round nuclei. The cytoplasm is scanty and basophilic and does not stain with mucicarmine, periodic acid-Schiff (PAS), or Sudan IV stains. These cells are found in the medium and large ducts of the salivary glands. The maternal cell is the progenitor of all other cell types. 
(4) Clear Cells
These variably sized and shaped cells have distinct outlines and a hydropic, water-clear cytoplasm. Their nuclei, usually centrally placed, are small, vesicular, or pyknotic (Fig. 6 ). On occasion, it seems that focally, there is a transition between epidermoid and clear cells. They do not stain with mucicarmine or fat stains and may or may not contain glycogen. 
(5) Columnar Cells
These cells resemble the cells found in the major secretory ducts of the salivary glands. They transform into mucous cells, and in this transitional form, their cytoplasm acquires a slight tendency to stain with mucicarmine stain.
(6) Mucous Cells
Because mucous cells occur in the normal ductular epithelium of the salivary glands, their appearance in a mucoepidermoid tumor is expected. Usually large, sometimes swollen or balloon-shaped, these cells have distinct cell boundaries (Fig. 7A) . Their small nuclei are usually compressed and located near the periphery of the cell. Their foamy or reticular cytoplasm is slightly basophilic and pale and gives a prominent positive reaction to mucicarmine and PAS stains. Metachromasia is also exhibited. Morphologically, mucous cells resemble intermediate, epidermoid, clear, and columnar cells. They occur in small clusters or are randomly distributed among other types of cells (Fig. 7B ).
Microscopic Appearance
The microscopic appearance of MEC depends greatly on the histologic grade of differentiation.
Prominent cystic structures are the hallmark of lowgrade MEC ( 10% of the tumor. Keratinization is seldom found. Microcystic formations coalescing into larger cysts are often prominent. A prominent fibrous stroma is often present. If the mucinous material in the cysts escapes into the stroma, an intense inflammatory reaction may obscure the true neoplastic nature of the lesion. The growth pattern of low-grade carcinomas is generally a broad advancing front; they are not highly invasive. Often, a lymphocytic infiltrate with possible germinal center formation is observed at the interface. No perineural or lymphovascular invasion is present.
Intermediate-grade lesions have fewer and smaller cysts than do low-grade lesions ( of atypia, anaplasia, multiple mitoses, and necrosis (Fig. 14) . These are infiltrative tumors in which perineural and lymphovascular invasion is easily found (Fig. 15) . High-grade carcinomas have scanty mucin production; thus, a careful search and special stains may be required to identify it. 
HISTOLOGIC GRADING
That is no uniformly accepted grading system for MEC exists despite nearly half a century of trying is testimony to a lack of consensus as to what histologic features are the most useful to formulate grades, whether 2 or 3 grades should apply, and an imperfect distinction among grade, as an independent prognostic variable, and the size of the neoplasm and its clinical stage. It must also be understood that the grading cannot substitute for an appropriate histologic classification. In that light, classifying only those MECs that are easily recognized distorts the clinical implications of grading. 2, 6 The 3-level grading approach to classifying tumors has found general acceptance among pathologists, and differences in biologic behavior can be demonstrated, even though clinical stage became a better prognosticator. 4, 6, 8 Suggested grading criteria for MEC have included, either singly or in combination, the relative proportion of cell types, degree of invasion, pattern of invasion, mitotic rate, proportion of tumor composed of cystic spaces relative to the solid growth degree of maturation, and neural and vascular invasion. 2, 3, 6 In 1945, Stewart et al 1 classified MEC as benign or malignant on the basis of the histologic appearance and clinical course. By 1953, Foote and Frazell 10 had collected data on 98 cases involving the major salivary glands. As metastasis had occurred with a few tumors previously classified as benign, the designations ''low-grade malignant'' and ''high-grade malignant'' were proposed. Clinical and pathologic data suggested that the use of low-grade, medium-grade, and high-grade malignant subgroups might be useful.
Jakobsson et al 4 and later Evans 26 championed 2-tiered low-grade and high-grade systems. Jakobsson et al 4 based their version solely on the presence or absence of ''invasive growth.'' Evans 26 ignored cell type and differentiation and defined high-grade carcinomas as those that had more than 90% solid architecture; all others were considered low-grade.
Batsakis and Luna 27 designed a 3-level grading system modified after the one proposed by Healey et al. 5 It incorporated cytodifferentiation and growth patterns, emphasized the intermediate cell population as an integral histogenetic and histologic component, and recognized poorly differentiated types of carcinoma (Table 1) . This 3-level grading system was clinically tested by Hicks et al 28 with success: In their series, the 5-year mortality rates were 0%, 30%, and 78% for patients with grade 1, 2, and 3 tumors, respectively. 28 Auclair et al 29 and Goode et al 30 from the AFIP demonstrated the inherent variability of interobserver grading for MEC, validating the need for easily implemented grading schema. These authors established more uniform and reproducible histologic criteria that correlated with clinical outcome. According to them, the histopathologic features that indicate aggressive behavior are a cystic component of less than 20% of the tumor area, 4 or more mitotic figures per 10 high-power fields, nerve invasion, tumor necrosis, and the presence of cellular anaplasia (cellular and nuclear pleomorphism, increased nuclear:cytoplasmic ratios, prominent or multiple nucleoli, and hyperchromasia). Each of these parameters was assigned a point value, and the sum of points for the 5 variables determined the tumor grade. A score of 0 to 4 was considered low-grade; 5 to 6, intermediate grade; and 7 or more, high grade ( Table 2 ). The 5-year mortality rates were 3.3%, 9.7%, and 46.3% for low-grade, intermediate-grade, and high-grade tumors, respectively. 29, 30 The authors acknowledged that their system was not reliable for submandibular tumors. 29, 30 Spiro and colleagues 6 found that submandibular gland tumors were the least predictable with respect to grade and stage. Guzzo et al 11 validated Auclair and Goode's grading method in their clinicopathologic study of 108 patients. In their study, the 5-year disease-free survival rate was 22.5% in patients with high-grade tumors and 97.0% in patients with low-grade tumors (P = 0.0066).
Brandwein and associates 31 found that the criteria proposed by Auclair et al 29 and Goode et al, 30 tended to downgrade MEC. They felt that their grading schema would benefit from the inclusion of additional findings (pattern of infiltration, vascular invasion, and bony invasion) and an upgrading of the points assigned to each histologic feature (Table 3) . In this system, grade I tumors have a score of 0; grade II, 2 or 3 points; and grade III, 4 or more points (Table 3 ). The local disease failure rates at 75 months were 0% for grade I MECs, 30% for grade II tumors, and 70% for grade III carcinomas. 31 It is important that the pathologists accept a standardized grading system that is easy to use and reproducible and results in more accurate and consistent grading of these rare neoplasms.
We graded 43 parotid MECs with the 3 systems discussed above and found that the system proposed by Batsakis and Luna 27 had the same distribution as the one proposed by Brandwein et al 31 and that the AFIP system 29, 30 tended to downgrade MEC (Table 4) . However, the Brandwein et al 31 and AFIP systems were easier to reproduce and more objective than the Batsakis and Luna system. 27 
HISTOLOGIC VARIANTS
Considerable variation exists in the type, distribution, and growth pattern of MEC cells. The histopathologic appearance of an MEC results from the interplay of these variations, with the cells arranging themselves in cystic or glandular structures, solid nests or cords, or a combination of these. A chronic inflammatory cell reaction, with or without fibrosis, is often seen. The combination of these histologic features results in different histologic appearances. 32 The sclerosing type of MEC epitomizes the pronounced hyalinization and fibrosis that can occur in MEC. This unusual but distinctive variant is microscopically characterized by extensive central sclerosis and peripheral lymphoid infiltrate (Fig. 16A) . Cystic epithelial islands typical of MEC are present in the midst of fibrotic tissue (Fig. 16B) . This subtype can be difficult to recognize and may be confused with chronic sialoadenitis or even metastasis to an intraparotid lymph node. All cases of sclerosing MEC reported in the medical literature have been of low-grade malignancies. 33, 34 The unicystic MEC of well-differentiated type can arise de novo or in a cyst (Fig. 17A ) (usually in a salivary duct cyst but occasionally in an odontogenic cyst). Histologically, the wall of the cyst is lined by welldifferentiated epidermoid, mucinous, and intermediate cells arranged in a single or multilayered pattern. Infiltration may be observed in several areas of the cystic wall 35 (Fig. 17B) .
Oncocytic differentiation has been found in a wide range of salivary gland neoplasms, including MEC. Usually, this differentiation is focal, but occasionally, the oncocytic elements comprise most of the lesion. By 1999, 6 parotid tumors had been reported in the medical literature under the term oncocytic MEC. Five were lowgrade, and the other was high-grade. 36 Histologically, this subtype of MEC has an extensive oncocytic component in addition to the typical features of MEC, especially mucous, intermediate, and epidermoid cells (Fig. 18A) . These typical components can be present focally. Therefore, an adequate number of histologic sections must be examined to identify the true nature of the neoplasm (Fig.  18B) . The other 3 MEC subtypes are the sebaceous variant, 37 clear cell variant 32, 38 (Fig. 19) , and goblet cell aggressive type (Fig. 20) . 31, 32 Two additional variants of MEC have been described-psammomatous and the spindle cell. The former needs further characterization; Kuo and Tsang 39 showed a photomicrograph of the psammomatous variant but did not provide any more details. Spindle cells in MEC are uncommon, and the occurrence of extensive areas of sarcomatoid, malignant cells has been reported only rarely (Fig. 21) . 40 Assessing the influence of neoplastic spindle cells on a patient's prognosis is difficult because only a few spindle cell MECs have been described. However, in the well-documented cases, the nonspindle cell epithelial component is of the high-grade type, and the prognosis has been poor. 40 MECs have been described involving Warthin tumors, pleomorphic adenomas, odontogenic cysts, and salivary duct cysts. 35, 41 The clinical behavior of these (23) 15 (35) secondary MECs depends on their degree of differentiation and size (Table 5) .
SPECIAL STUDIES Electron Microscopy
Three cell types can be distinguished by electron microscopic examination: intermediate, poorly differentiated cells with glycogen granules in cytoplasm (Fig.  22A) , typical epidermoid prickle cells with tonofilaments and desmosomes, (Fig. 22B) mucus-forming cells (Fig.  22C) . Small, hollow spaces are bounded by microvilli and contain secretory particles. Other features include clear cells with glycogen ( Fig. 22D ) and oncocytic areas rich in mitochondria. 42 
Immunohistochemical Analysis
In immunohistochemical studies of MEC, all cell types have reacted to cytokeratin (CK) except welldeveloped mucous cells, which generally do not react. Most tumor cells are immunoreactive to vimentin, S-100 protein, actin, a-fetoprotein, and carcinoembryonic antigen. 43 Immunoreactivity to monoclonal antibody B72.3 was strongest in MECs with prominent glandular differentiation. 44 MECs usually express, in different proportions, MUC1, MUC4, MUC5AC, and MUC5B; less frequently express MUC6; and rarely express MUC2 and MUC7. 45, 46 The immunohistochemical staining pattern of CK is not associated with the histologic grade of differentiation, 47 whereas high MUC1 expression is related to a high histologic grade, high recurrence and metastasis rates, and a short disease-free interval. Conversely, high expression of MUC4 is mainly related to low-grade, a low recurrence rate, and a long disease-free interval. 45, 46 Cytogenetic Analysis Many MECs have been reported to have the t(11:19)(q21;p13.1) translocation. This abnormality is also found in Warthin tumor 48 and clear cell hydradenoma of the skin. 49 
Molecular Genetics Analysis
The few molecular studies of MEC that exist involved limited numbers of cases. Infrequent genetic loss at chromosomes 9p21, 8q, 5p, 16q, and 12p was found. 50, 51 The H-ras gene was mutated at codon 12 or 13 in 18% of cases, and no mutations occurred at codon 61. 52 The mutations were mainly found in high-grade carcinomas. 53 
DIFFERENTIAL DIAGNOSIS
The differential diagnosis for MEC includes, but is not limited to, necrotizing sialometaplasia, inverted papilloma, squamous cell carcinoma (high-grade tumors), adenosquamous carcinoma, cystadenoma, cystadenocarcinoma, sebaceous carcinoma, and other clear cell tumors such as acinic cell carcinoma, hyalinizing clear cell carcinoma, clear cell oncocytoma, and metastatic renal cell carcinoma. 2, 3, 32 Necrotizing sialometaplasia rarely simulates lowgrade MEC; however, it retains the lobular architecture of the normal gland, exhibits lobular necrosis, and has smooth-edged cell nests. It lacks the cystic growth typical of low-grade MEC, and intermediate cells are not found. Inverted papillomas, like MEC, develop within excretory ducts. However, inverted papillomas are composed of more epidermoid cells than are MECs, and they do not infiltrate surrounding tissues as small cords of tumor cells. 2 Distinguishing low-grade MECs from cystadenoma may be difficult, and it may be impossible in small biopsies. The most important distinguishing features of MEC are the variable cell composition and infiltrative noncystic epithelial proliferation. Occasionally, MEC appears to develop from the epithelial lining of a cystadenoma; thus, adequate sampling is critical. 3 Cystadenocarcinomas lack epidermoid differentiation, do not have the variety of cell types characteristically present in MEC, and usually lack solid nests of neoplastic cells. 2, 3 Excessive intracellular keratinization and keratin pearl formation are features more common to primary or metastatic squamous cell carcinoma than to MEC. Squamous cell carcinomas do not involve goblet or signed ring cells with intracellular mucin, whereas high-grade MEC always involves at least a few mucin-containing cells. The monoclonal antibody B72.3 can be used to identify glandular differentiation in MEC. 43 Recently, Alos et al 45 and Handra-Luca et al 46 demonstrated that high-grade MECs express MUC5AC and MUC1, whereas squamous cell carcinomas do not. Also, high CK7 expression is more indicative of high-grade MEC than squamous cell carcinoma. 46 Squamous cell carcinomas are consistently negative for CK7 and CK20. 46 Adenosquamous cell carcinoma can be distinguished from MEC, as the glandular component can be distinguished from the squamous cell component. Intermediate cells are not found in adenosquamous cell carcinoma. In MEC, the squamous and mucinous components are usually intimately associated with each other in the same tumor nests.
Tumors with a predominance of clear cells, other than MEC, include epithelial-myoepithelial carcinoma and hyalinizing clear cell carcinoma. The clear cells in all 3 tumor types contain glycogen, but only the cells in MEC are associated with intracellular mucin. 32 In addition, epithelial-myoepithelial carcinoma has a characteristic biphasic pattern of cuboidal central cells surrounded by larger clear myoepithelial cells. 32 Polymorphous low-grade adenocarcinomas (PLGAs) may have cellular proliferations that resemble intermediate cells, and they may have focal mucinous and epidermoid differentiation. However, the growth pattern of PLGAs characteristically involves concentrically arranged cords of tumor cells and prominent perineural invasion, which are notably rare in MECs. Furthermore, PLGAs have multiple architectural arrangements, in contrast to the cystic and solid patterns often seen in MECs. 3 
PROGNOSIS AND PREDICTIVE FACTORS Clinical Factors
The prognosis of patients with MEC depends on the adequacy of treatment, the clinical stage, and the tumor grade and location. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Patients are more likely to experience a recurrence if the margins of resection are positive, regardless of grade. Healey et al 5 reported that 0 of 33 low-grade and intermediate-grade lesions recurred when the margins were free of carcinoma, but 6 of 12 of the same grade recurred when the margins were positive. Similarly, 13 of 16 high-grade lesions recurred when the margins were involved by tumor. Most of the tumors that recurred did so within 1 year of therapy. 5 However, delayed recurrences may occur. 5, 6 Clinical studies have clearly demonstrated the prognostic value of the clinical staging system in MEC (Table 6) . 6, 8, 54, 55 Spiro and associates 6 reported 5-year determinate cure rates of 97%, 83%, and 28% for stage I, II, and III tumors, respectively. The type of surgery performed was also based on the extent of the neoplasm (clinical stage) rather than the histologic appearance per se. 6, 8 Moreover, when a discrepancy existed between the grade and stage of a tumor (high-grade, stage I or lowgrade, stage III), the outcome was influenced more by the clinical stage than the histologic grade. 6 Plambeck et al 8 FIGURE 21 . Nest of malignant epithelial cells (arrow) within sarcomatous stroma (H&E Â 100). reported that all patients who died had had stage III or IV disease at initial diagnosis, and other studies found that the survival rate was significantly associated with the presence of nodal disease. 54, 55 Spiro et al 6 observed that metastases to regional lymph nodes occurred more frequently with submandibular tumors than with tumors of any other major or minor glands. 6 Also, base of the tongue and floor of the mouth locations suggest more aggressive behavior. 29 Distant MEC metastases imply a poor prognosis. Patients with distant metastases from minor and major gland tumors survive a mean of 2.3 and 2.6 years, respectively. 6 
Histologic Factors
Survival is closely related to histologic grade. 6, [26] [27] [28] [29] [30] [31] Although staging and grading are related, they seem to function independently of each other. Low-grade lesions behave less aggressively than do high-grade lesions, regardless of stage; conversely, stage I and II tumors have a better prognosis than do stage III or IV tumors, regardless of grade. 6 Hicks et al 28 and Brandwein and associates 31 reported 5-year mortality rates of 0%, 30%, and 78% for grade I, II, and III tumors, respectively. Auclair et al 29 and Goode et al 30 found mortality rates of 3.3%, 9.7%, and 46.3% for low-grade, intermediategrade, and high-grade tumors, respectively. Using the same histologic grading system, Guzzo et al 9 found 5-year disease-free survival rates of 28.5% for patients with highgrade carcinomas and 97.7% for patients with low-grade tumors.
Immunohistochemical Factors
The nuclear DNA content of MECs, as assessed by cytophotometric analysis and flow cytometry, demonstrates that diploid tumors have a favorable clinical course, and aneuploid tumors have an unfavorable course. 56 A high proliferating cell nuclear antigen score is associated with poor survival 57 ; similar results have been achieved using MIB-1 antigen. 58 Recently, Okabe et al 59 found that low p27 expression was a high risk factor for poor survival in patients with MEC, and Suziki et al 60 found that patients with MEC that overexpressed Her-2 neu had lower 5-year survival rates than did those with tumors with weak expression (25% vs. 81%). These findings allow for further stratification of patients with MEC, especially patients with grade 2 tumors, which have a variable and unpredictable clinical course (Table 7) .
Genetic Factors
No prognostically useful genetic factors have been identified. 61 
TREATMENT
Complete excision of the lesion with free surgical margins is the treatment of choice and the one that offers the best local control of the disease. [2] [3] [4] [5] [6] [7] [8] [9] [10] [26] [27] [28] [29] [30] [31] 62 However, the frozen section assessment of MEC surgical margins may be difficult because of ductal hyperplasia and squamous metaplasia in salivary gland tissue adjacent to the tumor and because microscopic islands of tumor may extend beyond the grossly discernible tumor mass.
Parotid tumors should be treated by parotidectomy, with preservation of the facial nerve; however, if the cervical lymph nodes are involved, neck dissection is indicated. For tumors of the submandibular gland, dissection of the triangle is recommended, and if cervical nodes are involved, a neck dissection is indicated. 6, 62 For carcinomas of the minor glands, complete excision with normal tissue margins is the ideal treatment. Radiation therapy is indicated for high-grade carcinomas, stage III and IV tumors, tumors with extensive perineural or vascular invasion, tumors of the deep lobe of the parotid gland or base of the tongue, and incompletely excised tumors. 63 The role of chemotherapy in the treatment of salivary MEC remains speculative. 2 However, with the emergence of molecular targeted therapy, salivary gland carcinomas are an optimal candidate for clinical trials of investigational and established drugs for other indications. 64, 65 
